Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care.
about
Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysisAntidepressants versus placebo for depression in primary careEarly onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysisIs remission of depressive symptoms in primary care a realistic goal? A meta-analysisA comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine: A 19-F MRS studySuggesting a Way to Understand the Actual Potential of Anti-Alzheimer's Disease Drugs That Show Promise in Transgenic Mouse ModelsSelective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential AnalysisWhy do some promising brain-stimulation devices fail the next steps of clinical development?Depression in primary care: interpersonal counseling vs selective serotonin reuptake inhibitors. The DEPICS Study. A multicenter randomized controlled trial. Rationale and design.Subchronic SSRI administration reduces insula response during affective anticipation in healthy volunteers.Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: a randomized, open-label controlled trial.Escitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression.Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic reviewStereochemistry in Drug ActionEfficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysisEfficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysisEscitalopram therapy for major depression and anxiety disorders.Escitalopram.Effects of chronic treatment with escitalopram or citalopram on extracellular 5-HT in the prefrontal cortex of rats: role of 5-HT1A receptorsStereochemistry and drug efficacy and development: relevance of chirality to antidepressant and antipsychotic drugs.Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis.Escitalopram: A New SSRI for the Treatment of Depression in Primary Care.Treatment of Adults With Treatment-Resistant Depression: Electroconvulsive Therapy Plus Antidepressant or Electroconvulsive Therapy Alone? Evidence From an Indirect Comparison Meta-Analysis.Efficacy and safety of generic escitalopram (Lexacure(®)) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study.Escitalopram in obsessive-compulsive disorder: a case series.Managing depressive and anxiety disorders with escitalopram.Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability.Effect of age, weight, and CYP2C19 genotype on escitalopram exposure.An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical features.The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders.Escitalopram in the treatment of obsessive-compulsive disorder.Escitalopram for the treatment of major depression and anxiety disorders.Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder.Escitalopram reduces hot flashes in nondepressed menopausal women: A pilot study.Does study design influence outcome?. The effects of placebo control and treatment duration in antidepressant trials.The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram.Less is more in antidepressant clinical trials: a meta-analysis of the effect of visit frequency on treatment response and dropout.The Effect of Escitalopram on Mood and Cognition in Depressive Alzheimer's Disease Subjects.Current treatment options: relief of symptoms and ultimate recovery.Unique mechanism of action for escitalopram: does it hold the promise?
P2860
Q21143851-073C19F4-352A-414F-92F2-E953E78A601CQ24239979-CBD50F44-7E0B-4708-A97A-0AED37F59ABAQ24647799-0A2034C9-8F26-43D8-9419-F7C07418DEB0Q24794437-C5E7A5FE-7434-4296-80DD-6EBADF44F27FQ28249891-518B5416-57AC-41B4-9B7A-FA3C670FCFCBQ28606794-AE6F71B8-5F9D-4BE2-8F32-AD3ABC230815Q28736049-9C18E10A-CEA2-4602-B5EE-417CB97833D5Q33519672-B1D79512-027E-4BA4-8103-A5ABB7FAD7CEQ33756147-F81E3F62-B05B-4371-8FEC-5E34482C795BQ33758489-77B3A38F-8854-4A9C-924C-B95E45FEEB69Q33987315-AAED943C-43D2-4995-829C-C6B7C43872D5Q34072466-3E85A2C8-1532-450A-AE4A-D5BA5D132A07Q34240696-FE90812B-BF2A-437A-86CF-C5CD5FBAF895Q34322267-70F79E8D-97D8-46FE-BA5E-43B163037406Q34480541-9C8A436E-FB9D-4D2F-88AC-AD803C3B0B48Q34629445-3052CF20-3D4F-4D15-94A7-19FBD0AE4A9FQ34685982-5E17FD83-C4F0-4BEE-87E3-A317092FA8CFQ34974884-755842D9-EB79-46D0-98EA-C33B188A979DQ35047176-01BC0EA5-0CD7-4FD8-A070-4FDC98532CD8Q35054997-ADB72EE0-5E75-4357-8998-A8B2B22C3916Q35066804-C6B46272-ACCC-458F-AE89-E8BF87B3B067Q35160849-B3D7B00B-4F85-45EA-A91C-9147647FDCB2Q35857837-BA63AD90-7438-4429-8693-B6C3BBEDFE1FQ36160446-D53DAA39-3030-403B-91BF-1E0FF1C4566FQ36274266-C92D21B3-C1D1-4165-B698-86C0EEEB8706Q36407369-E916CC64-605F-4E6B-924B-D5BB56DC0A04Q36479510-8DD1FA39-A2CE-4D0B-A3AE-2B5B341631A3Q36606190-A6CC34AC-E9F7-4302-9580-B32C766A53B7Q36746631-9CDBF296-AD71-42B8-9E00-6C9E4F9E47B1Q36960563-DFB85CE0-F298-4711-9C18-3845DDD852EAQ37111879-3C5A3628-5EB5-40E1-A126-2AEB29833CAFQ37139768-4316CA4A-4317-4D52-B90D-7F1614BA6024Q37156421-E259617D-64FF-44DE-9BD1-143AB724F176Q37195414-E8A44A97-E476-45A0-8A9A-09C5A13A1D97Q37202188-8A7800B9-C8B4-4ACF-BFA2-FBA94E30D4B9Q37207545-FBA6EA30-96DB-40F5-BA6A-43010D060514Q37503551-D74F8E70-6A92-4482-B3D7-CC7242326718Q38813696-AD48D568-E2A2-42A8-B956-2BAA669CE2D0Q39357187-281044A9-69AB-4110-92D3-36E78A5673C5Q39386249-AC1E4EF8-EE0A-4CD0-A410-FDD4D1E9733B
P2860
Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Escitalopram 10 mg/day is effe ...... in depression in primary care.
@en
Escitalopram 10 mg/day is effe ...... in depression in primary care.
@nl
type
label
Escitalopram 10 mg/day is effe ...... in depression in primary care.
@en
Escitalopram 10 mg/day is effe ...... in depression in primary care.
@nl
prefLabel
Escitalopram 10 mg/day is effe ...... in depression in primary care.
@en
Escitalopram 10 mg/day is effe ...... in depression in primary care.
@nl
P2093
P1476
Escitalopram 10 mg/day is effe ...... in depression in primary care.
@en
P2093
Bang Hedegaard K
Michael Lemming O
P304
P356
10.1097/00004850-200205000-00001
P577
2002-05-01T00:00:00Z